Search in:

Advanced search

Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 10

Submit an article Journal homepage

341

Views

CrossRef citations to date

Altmetric

Reviews

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

Gianluca Papeo Nerviano Medical Sciences, Department of Medicinal Chemistry, Italy

Barbara Forte Nerviano Medical Sciences, Department of Medicinal Chemistry, Italy

Paolo Orsini Nerviano Medical Sciences, Department of Medicinal Chemistry, Italy

Claudia Perrera Nerviano Medical Sciences, Department of Biotechnology, Italy

Helena Posteri Nerviano Medical Sciences, Department of Medicinal Chemistry, Italy

Alessandra Scolaro Nerviano Medical Sciences, Department of Medicinal Chemistry, Italy

Alessia Montagnoli Nerviano Medical Sciences, Department of Cell Biology, Viale Pasteur 10, 20014 Nerviano (MI), Italy +039 033 158 1071; +039 033 158 1233; [email protected]

show all

Pages 1377-1400 | Published online: 10 Sep 2009

Cite this article
https://doi.org/10.1517/13543770903215883

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Otto H, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly (ADP)-rybosyl) transferases (pARTs). BMC Genomics 2005;6:139
PubMed Web of Science ®Google Scholar
D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249-68
PubMed Web of Science ®Google Scholar
Le Rhun Y, Kirkland JB, Shah GM. Cellular responses to DNA damage in the absence of poly (ADP-ribose) polymerase. Biophys Res Commun 1998;245:1-10
PubMed Web of Science ®Google Scholar
De Murcia JM, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-63
PubMedGoogle Scholar
Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenilic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963;11:39-43
PubMed Web of Science ®Google Scholar
Kinoshita T, Nakanishi I, Warizaya M, et al. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett 2004;556:43-6
PubMed Web of Science ®Google Scholar
Petrucco S. Sensing DNA damage by PARP-like fingers. Nucleic Acids Res 2003;31:6689-99
PubMedGoogle Scholar
de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997;94:7303-7
PubMed Web of Science ®Google Scholar
Wang ZQ, Auer B, Stingl L, et al. Mice lacking ADPRT and poly (ADP-rybosyl) ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509-20
PubMed Web of Science ®Google Scholar
Masutani M, Nozaki T, Nakamoto K, et al. The response of Parp knockout mice against DNA damaging agents. Mutat Res 2000;462:159-66
PubMed Web of Science ®Google Scholar
Shieh WM, Ame JC, Wilson MV, et al. Poly (ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem 1998;273:30069-72
PubMed Web of Science ®Google Scholar
Ame JC, Rolli V, Schreiber V, et al. PARP-2 a novel mammalian DNA damage dependent poly (ADP-ribose) polymerase. J Biol Chem 1999;274:17860-8
PubMed Web of Science ®Google Scholar
Oliver AW, Ame JC, Roe SM, et al. Crystal structure of the catalytic fragment of murine poly (ADP) ribose polymerase-2. Nucleic Acids Res 2004;32:456-64
PubMed Web of Science ®Google Scholar
Yelamos J, Schreiber V, Dantzer F. Toward specific functions of poly (ADP-ribose) polymerase-2. Trends Mol Med 2008;14:169-78
PubMed Web of Science ®Google Scholar
Menissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-63
PubMed Web of Science ®Google Scholar
Schreiber V, Ame JC, Dolle P, et al. Poly (ADP-ribose) polymerase–2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002;277:23028-36
PubMed Web of Science ®Google Scholar
Yelamos J, Monreal Y, Saenz L, et al. PARP-2 deficiency affects the survival of CD4+ and CD8+ double positive thymocytes. EMBO J 2006;25:4350-60
PubMed Web of Science ®Google Scholar
Moroni F, Formentini L, Gerace E, et al. Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. Brain J Pharmacol 2009;157:854-62
PubMed Web of Science ®Google Scholar
Rouleau M, McDonald D, Gagné P, et al. PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery. J Cell Biochem 2007;100:385-401
PubMedGoogle Scholar
Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly (ADP-ribose) polymerase at human telomeres. Science 1998;282:1484-7
PubMed Web of Science ®Google Scholar
Hsiao SJ, Smith S. Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ. J Cell Biol 2009;184:515-26
PubMed Web of Science ®Google Scholar
Chiang J, Hsiao SJ, Yver D, et al. Tankyrase 1 and Tankyrase 2 are essential but redundant for mouse embryonic development. PloS ONE 2008;3:1-10
Google Scholar
Cho SH, Goenka S, Henttinen T, et al. PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 2009;113:2416-25
PubMed Web of Science ®Google Scholar
Myknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly (ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-82
PubMedGoogle Scholar
Nguewa PA, Fuertes MA, Cepeda V, et al. Poly (ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2006;2:47-53
PubMedGoogle Scholar
Jagtap P, Szabo C. Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40
PubMed Web of Science ®Google Scholar
De la Lastra CA, Villegas I, Sanchez-Fidalgo S. Poly (ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 2007;13:933-62
PubMed Web of Science ®Google Scholar
Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6:2860-7
PubMed Web of Science ®Google Scholar
Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52:25-33
PubMed Web of Science ®Google Scholar
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA-2-deficient tumors with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7
PubMed Web of Science ®Google Scholar
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defects in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
PubMed Web of Science ®Google Scholar
McCabe N, Lord CJ, Tutt AN, et al. BRCA-2 deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency. Cancer Biol Ther 2005;4:934-6
PubMed Web of Science ®Google Scholar
Gudmundsdottir K, Ashworth A. The roles of BRCA-1 and BRCA-2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864-74
PubMed Web of Science ®Google Scholar
Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57
PubMed Web of Science ®Google Scholar
Moynahan ME, Chiu JW, Koller BH, et al. BRCA-1 controls homology-directed DNA repair. Mol Cell 1999;4:511-8
PubMed Web of Science ®Google Scholar
Moynahan ME, Pierce AJ, Jasin M. BRCA-2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72
PubMed Web of Science ®Google Scholar
Tutt A, Bertwistle D, Valentine J, et al. Mutation in BRCA-2 stimulates error-prone homology-directed repair of the DNA double strand breaks occurring between repeated sequences. EMBO J 2001;20:4704-16
PubMed Web of Science ®Google Scholar
Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002;16:8981-93
Google Scholar
Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-6
PubMed Web of Science ®Google Scholar
Radice P. Mutations of BRCA genes in hereditary breast and ovarian cancer. J Exp Clin Cancer Res 2002;21:9-12
PubMedGoogle Scholar
Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98
PubMed Web of Science ®Google Scholar
Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer 2004;4:814-9
PubMed Web of Science ®Google Scholar
Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Res 1998;90:1138-45
PubMedGoogle Scholar
Wei M, Grushko TA, Dignam J, et al. BRCA-1 promoter methylation in sporadic breast cancer is associated with reduced BRCA-1 copy number and chromosome 17 aneusomy. Cancer Res 2005;65:10692-9
PubMed Web of Science ®Google Scholar
Catteau A, Harris WH, Xu CF, et al. Methylation of the BRCA-1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999;18:1957-65
PubMed Web of Science ®Google Scholar
Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA-1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9
PubMed Web of Science ®Google Scholar
Seal S, Barfoot R, Jayatilake H, et al. Evaluation of Fanconi anemia genes in familial breast cancer predisposition. Cancer Res 2003;63:8596-9
PubMed Web of Science ®Google Scholar
Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-35
PubMed Web of Science ®Google Scholar
Rodriguez C, Hughes Davies L, Valles H, et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 2004;10:5785-91
PubMed Web of Science ®Google Scholar
Bane AL, Weerasooriya N, Andrulis IL, et al. BRCA2 deficiency and EMSY amplification: possible mutually exclusive genetic events in the development of breast cancer. Mod Pathol 2007;88:88
Google Scholar
Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 2001;54:512-6
PubMed Web of Science ®Google Scholar
Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5
PubMed Web of Science ®Google Scholar
Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006;25:5912-9
PubMed Web of Science ®Google Scholar
Matsuura S, Kobayashi J, Tauchi H, Komatsu K. Nijmegen breakage syndrome and DNA double strand break repair by NBS1 complex. Adv Biophys 2004;38:65-80
Google Scholar
Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6:556-68
PubMed Web of Science ®Google Scholar
Yu SW, Wang H, Poitras MF, et al. Mediation of poly (ADP-ribose) polymerase 1-dependent cell death by apoptosis-inducing factor. Science 2002;297:259-63
PubMed Web of Science ®Google Scholar
Hassa PO, Hottinger MO. A role for poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem 1999;380:953-9
PubMed Web of Science ®Google Scholar
Yap TA, Boss DS, Fong PC, et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA-1/2 mutation carriers. J Clin Oncol 2007;25(18S):3529
Web of Science ®Google Scholar
Menear KA, Adcock C, Boulter R, et al. 4-(3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl)-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91
PubMed Web of Science ®Google Scholar
Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;15;3916-25
Google Scholar
Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;4:17079-84
Google Scholar
Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCAdeficient advanced ovarian cancer [abstract 5500]. J Clin Oncol 2009;27:15s
Google Scholar
Tutt A, Robson M, GarberPhase JE, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA deficient advanced breast cancer [abstract CRA501]. J Clin Oncol 2009;27:18s
Google Scholar
Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly (ADP ribose) polymerase inhibitor for clinical trials. Mol Cancer Ther 2007;6:945-56
PubMed Web of Science ®Google Scholar
Plummer R, Jones C, Middleton M, et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-23
PubMed Web of Science ®Google Scholar
Patcher P, Liaudet L, Mabley JG, et al. Beneficial effects of a novel ultrapotent poly (ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 2006;17:369-75
PubMedGoogle Scholar
Morrow DA, Brickman CM, Murphy SA, et al. A randomized, placebo controlled trial to evacuate the tolerability, safety, pharmocokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous intervention: results of the TIMI 37 trial. J Thromb Thrombolysis 2009;27:359-64
PubMedGoogle Scholar
Dhein S, Krause N, Ullmann C, et al. Ischemic and inflammatory lung impairment by extracorporeal circulation: effect of PARP-inhibition by INO-1001. Pharmacol Res 2008;58:332-9
PubMedGoogle Scholar
Bedikian AY, Papadopoulos NE, Kim KB, et al. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subject with unresectable stage-III or IV melanoma. Cancer Invest 2009;13:1
Google Scholar
Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trials of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:1-9
PubMedGoogle Scholar
Donawho CK, Luo Y, Peniing TD, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37
PubMed Web of Science ®Google Scholar
Penning TD, Zhu GD, Gandhi VS, et al. Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-(R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 2009;52:514-23
PubMed Web of Science ®Google Scholar
Palma JP, Rodriguez LE, Bontcheva-Diaz VD, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28:2625-35
PubMed Web of Science ®Google Scholar
Iwashita A, Hattori K, Yamamoto H, et al. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly (ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett 2005;579:1389-93
PubMed Web of Science ®Google Scholar
Kinoshita T, Nakanishi I, Warizaya M, et al. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett 2004;556:43-6
PubMed Web of Science ®Google Scholar
Pellicciari R, Camaioni E, Costantino G, et al. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. ChemMedChem 2008;3:914-23
PubMed Web of Science ®Google Scholar
Lehtiö L, Collins R, van den Berg S, et al. Zinc binding catalytic domain of human Tankyrase 1. J Mol Biol 2008;379:136-45
PubMed Web of Science ®Google Scholar
Lehtio L, Jemth AS, Collins R, et al. Structural basis for inhibitor specificity in human poly (ADP-ribose) polymerase-3. J Med Chem 2009;52:3108-11
PubMed Web of Science ®Google Scholar
Peukert S, Schwahn U. New inhibitors of poly(ADP-ribose)polymerase (PARP). Expert Opin Ther Patents 2004;14:1531-51
Web of Science ®Google Scholar
Li H, Goldstein BM. Carboxamide group conformation in the nicotinamide and thiazole-4-carboxamide rings: implications for enzyme binding. J Med Chem 1992;35:3560-7
PubMedGoogle Scholar
Ruf A, Menissier de Murcia G, Schulz GE. Structure of the catalytic fragment of poly (AD-ribose) polymerase from chicken. Proc Natl Acad Sci USA 1996;93:7481-5
PubMed Web of Science ®Google Scholar
Cepeda V, Fuertes MA, Castilla J, et al. Poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Rec Pat Anticancer Drug Disc 2006;1:39-53
PubMedGoogle Scholar
Mendeleyev J, Kirsten E, Hakam A, et al. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 1995;50:705-14
PubMed Web of Science ®Google Scholar
Ono Pharm Co Ltd. WO200044726; 2000
Google Scholar
Kudos Pharm Ltd/Maybridge Ltd. WO2004080976; 2004
Google Scholar
Kudos Pharm Ltd/Maybridge Ltd. WO200236576; 2002
Google Scholar
Kudos Pharm Ltd. WO2006021801; 2006
Google Scholar
Kudos Pharm Ltd. WO2008047082; 2008
Google Scholar
Kudos Pharm Ltd. WO2009050469; 2009
Google Scholar
Kudos Pharm Ltd. WO2008122810; 2008
Google Scholar
Abbott. WO2008083027; 2008
Google Scholar
Kudos Pharm Ltd. WO2006067472; 2006
Google Scholar
Menear KA, Adcock C, Cuenca Alonso F, et al. Novel alkoxybenzamide inhibitors of poly (ADP-ribose) polymerase. Bioorg Med Chem Lett 2008;18:3942-5
PubMedGoogle Scholar
Kudos Pharm Ltd. WO2007144637; 2007
Google Scholar
AstraZenecka AB. WO2008146035; 2008
Google Scholar
Cancer Research Technology Ltd. WO05012305; 2005
Google Scholar
Pfizer Inc/Cancer Research Tech Ltd. WO06033003; 2005
Google Scholar
Pfizer, Inc. WO04087713; 2004
Google Scholar
BiPar Sciences, Inc. WO20061358732; 2006
Google Scholar
BiPar Sciences, Inc. WO2007011962; 2007
Google Scholar
BiPar Sciences, Inc. WO2008030887; 2008
Google Scholar
Newcastle Univ Ventures, Ltd. US6100283; 2000
Google Scholar
Newcastle Univ Ventures, Ltd. US6310082; 2001
Google Scholar
Abbott. WO2006110816; 2006
Google Scholar
Abbott. WO2007041357; 2007
Google Scholar
Abbott. WO2009012280; 2009
Google Scholar
Costantino G, Macchiarulo A, Campioni E, Pellicciari R. Modeling of poly (ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. J Med Chem 2001;44:3786-94
PubMed Web of Science ®Google Scholar
Penning TD, Zhu G-D, Gandhi VB, et al. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem 2008;16:6965-75
PubMed Web of Science ®Google Scholar
White AW, Almassyr R, Calvert AH, et al. Resistance-modifying agents 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med Chem 2000;43:4084-97
PubMed Web of Science ®Google Scholar
Canan Koch SC, Thoresen LH, Jayashree GT, et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem 2002;45:4961-74
PubMed Web of Science ®Google Scholar
Hattori K, Kido Y, Yamamoto H, et al. Rational approaches of discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem 2004;47:4151-4
PubMed Web of Science ®Google Scholar
Zhu GD, Gong J, Penning TD, et al. Discovery and SAR of highly potent, orally efficacious inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. MEDI 479, oral presentation at the 236th ACS National Meeting, Philadelphia, PA, August 17-21, 2008
Google Scholar
Zhu GD, Hannick SM, Penning TD, et al. Asymmetric syntheses of substituted 2-aryl-pyrrolidines and -piperidines and application to the syntheses of orally efficacious PARP inhibitors. ORGN 381, Oral presentation at the 236th ACS National Meeting, Philadelphia, PA, August 17-21, 2008
Google Scholar
Abbott. WO2007095628; 2007
Google Scholar
Abbott. WO2008082887; 2008
Google Scholar
Abbott. WO2007149907; 2007
Google Scholar
Aventis Pharm, Inc. WO05097750; 2005
Google Scholar
Sanofi-Aventis Deutschland GMBH. WO06042638; 2006
Google Scholar
Sentinel Oncology Ltd. WO08015429; 2008
Google Scholar
Yamanouchi Pharm. WO03062234; 2003
Google Scholar
Fujisawa Pharm Co Ltd. WO03007959; 2003
Google Scholar
Cylene Pharmaceuticals, Inc. WO08028168; 2008
Google Scholar
MGI Guilford Pharm, Inc. WO06078711; 2006
Google Scholar
Guilford Pharm, Inc. WO04105700; 2004
Google Scholar
MGI Guilford Pharm, Inc. WO07051119; 2007
Google Scholar
Altana Pharma AG. WO04108723; 2004
Google Scholar
Janssen Pharmaceutica NV. WO2005/054209; 2005
Google Scholar
Janssen Pharmaceutica NV. WO2005/054201; 2005
Google Scholar
Janssen Pharmaceutica NV. WO2008/107478; 2008
Google Scholar
Inotek Pharmaceutical Corporation. WO2007/025009; 2007
Google Scholar
Inotek Pharmaceutical Corporation. WO2008106619; 2008
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2007113596; 2007
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2008084261; 2008
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2007144669; 2007
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2008090379; 2008
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2007138351; 2007
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2007138355; 2007
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2008001134; 2008
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2008041037; 2008
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2008017883; 2008
Google Scholar
IST Ricerche Biol Mol P Angeletti SPA. WO2008056187; 2008
Google Scholar
Finn RD, Tate J, Mistry J, et al. The Pfam protein families database. Nucleic Acids Res 2008;Database Issue 36:D281-8 and/or UniProt Knowledgebase annotations
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date